Literature DB >> 29621951

Patient-level outcomes and virologic suppression rates in HIV-infected patients receiving antiretroviral therapy in Rwanda.

David J Riedel1, Kristen A Stafford1,2, Peter Memiah3, Modupe Coker4, Cyprien Baribwira5, Jackson Sebeza5, Eva Karorero5, Sabin Nsanzimana6, Fernando Morales7, Robert R Redfield1.   

Abstract

The Rwanda national HIV program has been successful at scaling up antiretroviral therapy (ART) to achieve universal access. The AIDSRelief Model of Care focuses on four key principles: (1) earlier initiation of ART; (2) use of durable, highly-potent, and sequence-friendly first-line ART regimens; (3) early detection of treatment failure; and (4) provision of community-based care and support to ensure optimal adherence and follow up/engagement in care. We conducted a retrospective cohort study of randomly-selected HIV-infected patients at AIDSRelief-supported sites using a stratified, random sample of 583 adults (>15 years) who initiated ART from 30 June 2008 to 1 February 2010. At ART initiation, the median patient age was 38 years, and 67% were female. The baseline median CD4+ cell count was 309 cells/mm3. Overall virologic suppression was 91%. Married/ever married status (adjusted prevalence odds ratio [aPOR] 3.75, 95% confidence interval [CI] 1.30-10.78) and self-reported adherence ≥95% in the past month (aPOR 2.76, 95% CI 1.00-7.62) were significantly associated with viral suppression in the multivariable model. Excellent virologic outcomes were achieved in Rwandan AIDSRelief sites utilizing the AIDSRelief Model of Care during the scale-up of ART in the country.

Entities:  

Keywords:  AIDSRelief; HIV; Rwanda; virologic outcomes, antiretroviral therapy

Mesh:

Substances:

Year:  2018        PMID: 29621951     DOI: 10.1177/0956462418761695

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  4 in total

1.  Predictive factors of viral load high-risk events for virological failure in HIV/AIDS patients receiving long-term antiviral therapy.

Authors:  Shanfang Qin; Jingzhen Lai; Hong Zhang; Di Wei; Qing Lv; Xue Pan; Lihua Huang; Ke Lan; Zhihao Meng; Hao Liang; Chuanyi Ning
Journal:  BMC Infect Dis       Date:  2021-05-18       Impact factor: 3.090

Review 2.  Systematic review: Development of a person-centered care framework within the context of HIV treatment settings in sub-Saharan Africa.

Authors:  Malia Duffy; Caitlin Madevu-Matson; Jessica E Posner; Hana Zwick; Melissa Sharer; Antonia M Powell
Journal:  Trop Med Int Health       Date:  2022-04-01       Impact factor: 3.918

3.  Prevalence and Predictors of Persistent Human Immunodeficiency Virus Viremia and Viral Rebound After Universal Test and Treat: A Population-Based Study.

Authors:  M Kate Grabowski; Eshan U Patel; Gertrude Nakigozi; Victor Ssempijja; Robert Ssekubugu; Joseph Ssekasanvu; Anthony Ndyanabo; Godfrey Kigozi; Fred Nalugoda; Ronald H Gray; Sarah Kalibbala; David M Serwadda; Oliver Laeyendecker; Maria J Wawer; Larry W Chang; Thomas C Quinn; Joseph Kagaayi; Aaron A R Tobian; Steven J Reynolds
Journal:  J Infect Dis       Date:  2021-04-08       Impact factor: 7.759

Review 4.  Men missing from the HIV care continuum in sub-Saharan Africa: a meta-analysis and meta-synthesis.

Authors:  Maria F Nardell; Oluwatomi Adeoti; Carson Peters; Bernard Kakuhikire; Caroline Govathson-Mandimika; Lawrence Long; Sophie Pascoe; Alexander C Tsai; Ingrid T Katz
Journal:  J Int AIDS Soc       Date:  2022-03       Impact factor: 5.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.